With an aim to expand in the field of genomic-based diagnostic tools, Illumina Inc. (ILMN), a major developer of life science tools for large-scale genetic analysis, recently acquired UK based ...
Illumina Acquires BlueGnome, Leading Provider of Cytogenetics and In Vitro Fertilization Screening S
SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (NAS: ILMN) today announced that it has acquired Cambridge, U.K.-based BlueGnome Ltd. for an undisclosed sum. BlueGnome, now a wholly owned subsidiary of ...
Illumina acquired BlueGnome, a U.K. firm that provides products for screening for genetic abnormalities associated with developmental delay, cancer, and infertility. Founded in 2002, BlueGnome ...
DNA analytics company Illumina announced today that it has acquired BlueGnome, a diagnostics company based in Cambridge, U.K., that specializes in chromosomal screening for reproductive health and ...
BlueGnome’s continued growth has been recognized by The Deloitte Technology Fast 50, one of the UK’s foremost technology award programmes. BlueGnome was ranked the fastest growing biotechnology ...
Following the launch of its CytoChip Focus arrays for haematological and constitutional research, BlueGnome announced the release of its first oligo array solution for cytogenetics. The arrays will be ...
Illumina Acquires BlueGnome, Leading Provider of Cytogenetics and In Vitro Fertilization Screening S
Illumina Acquires BlueGnome, Leading Provider of Cytogenetics and In Vitro Fertilization Screening Solutions Acquisition Supports Illumina Goals in Diagnostics, Enhances Position in Reproductive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback